Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Syntara Limited ( (AU:SNT) ) is now available.
Syntara has advanced its clinical pipeline with U.S. FDA feedback endorsing the Phase 2b trial design for lead myelofibrosis drug amsulostat, while the Garvan Institute secured A$3 million in grant funding to run a Phase 1/2 trial of the same agent in advanced pancreatic cancer at no cost to the company. Recruitment in a Phase 2 trial of SNT-4728 for isolated REM Sleep Behaviour Disorder has been completed, with top-line data due in the second quarter of 2026, positioning the asset as a potential early-intervention therapy in neurodegenerative disease.
The company’s funding base strengthened over the March quarter, with a A$1.7 million milestone payment from Parkinson’s UK, a pro forma cash balance of A$16.9 million and firm commitments for an additional A$8 million via an institutional placement plus a planned A$2 million share purchase plan. Management flagged five clinical data readouts expected in 2026, suggesting a potentially transformative year for Syntara’s value proposition and partnership prospects as it moves amsulostat into late-stage development and broadens non-dilutive funding across four studies.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited is an ASX-listed clinical-stage drug development company focused on novel therapies for myelofibrosis, neurodegenerative disease and advanced cancers. Its pipeline includes lead candidate amsulostat for hematologic and solid tumours, and SNT-4728, a first-in-class neuro-targeted anti-inflammatory therapy targeting early-stage neurodegenerative conditions such as isolated REM Sleep Behaviour Disorder.
Average Trading Volume: 837,016
Technical Sentiment Signal: Sell
Current Market Cap: A$52.3M
For detailed information about SNT stock, go to TipRanks’ Stock Analysis page.